AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $368.19 billion. The enterprise value is $431.33 billion.
Important Dates
The last earnings date was Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Apr 15, 2026 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 75.42% |
| Float | 1.77B |
Valuation Ratios
The trailing PE ratio is 102.54 and the forward PE ratio is 13.98. AbbVie's PEG ratio is 0.89.
| PE Ratio | 102.54 |
| Forward PE | 13.98 |
| PS Ratio | 5.86 |
| Forward PS | 5.31 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.89 |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 119.98 |
| EV / Sales | 6.87 |
| EV / EBITDA | 14.38 |
| EV / EBIT | 19.72 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.25 |
| Debt / FCF | n/a |
| Interest Coverage | 7.51 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 22.24% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.40% |
| Revenue Per Employee | $1.10M |
| Profits Per Employee | $63,070 |
| Employee Count | 57,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, AbbVie has paid $2.33 billion in taxes.
| Income Tax | 2.33B |
| Effective Tax Rate | 39.06% |
Stock Price Statistics
The stock price has increased by +4.88% in the last 52 weeks. The beta is 0.30, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +4.88% |
| 50-Day Moving Average | 214.20 |
| 200-Day Moving Average | 218.02 |
| Relative Strength Index (RSI) | 50.80 |
| Average Volume (20 Days) | 6,905,003 |
Short Selling Information
The latest short interest is 21.85 million, so 1.24% of the outstanding shares have been sold short.
| Short Interest | 21.85M |
| Short Previous Month | 25.11M |
| Short % of Shares Out | 1.24% |
| Short % of Float | 1.24% |
| Short Ratio (days to cover) | 3.06 |
Income Statement
In the last 12 months, AbbVie had revenue of $62.82 billion and earned $3.60 billion in profits. Earnings per share was $2.03.
| Revenue | 62.82B |
| Gross Profit | 45.25B |
| Operating Income | 21.87B |
| Pretax Income | 5.98B |
| Net Income | 3.60B |
| EBITDA | 30.00B |
| EBIT | 21.87B |
| Earnings Per Share (EPS) | $2.03 |
Full Income StatementBalance Sheet
The company has $5.26 billion in cash and $68.40 billion in debt, with a net cash position of -$63.14 billion or -$35.70 per share.
| Cash & Cash Equivalents | 5.26B |
| Total Debt | 68.40B |
| Net Cash | -63.14B |
| Net Cash Per Share | -$35.70 |
| Equity (Book Value) | -3.23B |
| Book Value Per Share | -1.85 |
| Working Capital | n/a |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 8.13B |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 72.03%, with operating and profit margins of 34.81% and 5.79%.
| Gross Margin | 72.03% |
| Operating Margin | 34.81% |
| Pretax Margin | 9.51% |
| Profit Margin | 5.79% |
| EBITDA Margin | 47.76% |
| EBIT Margin | 34.81% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 3.32%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 3.32% |
| Dividend Growth (YoY) | 5.64% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 332.01% |
| Buyback Yield | -0.04% |
| Shareholder Yield | 3.28% |
| Earnings Yield | 0.98% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for AbbVie is $254.82, which is 22.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $254.82 |
| Price Target Difference | 22.42% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (5Y) | 5.05% |
| EPS Growth Forecast (5Y) | 31.91% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
